BR112015000368A2 - forma de tri-sais de metformina - Google Patents
forma de tri-sais de metforminaInfo
- Publication number
- BR112015000368A2 BR112015000368A2 BR112015000368A BR112015000368A BR112015000368A2 BR 112015000368 A2 BR112015000368 A2 BR 112015000368A2 BR 112015000368 A BR112015000368 A BR 112015000368A BR 112015000368 A BR112015000368 A BR 112015000368A BR 112015000368 A2 BR112015000368 A2 BR 112015000368A2
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes
- metformin
- tri
- compounds
- functional groups
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003105 metformin Drugs 0.000 title abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000524 functional group Chemical group 0.000 abstract 4
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 208000006011 Stroke Diseases 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 2
- 206010003119 arrhythmia Diseases 0.000 abstract 2
- 229940009098 aspartate Drugs 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- 208000010125 myocardial infarction Diseases 0.000 abstract 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 1
- 229940000640 docosahexaenoate Drugs 0.000 abstract 1
- 229940066279 eicosapentaenoate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261669763P | 2012-07-10 | 2012-07-10 | |
| US201261670368P | 2012-07-11 | 2012-07-11 | |
| US201261670376P | 2012-07-11 | 2012-07-11 | |
| US13/841,970 US8765811B2 (en) | 2012-07-10 | 2013-03-15 | Tri-salt form of metformin |
| PCT/US2013/049984 WO2014011814A1 (en) | 2012-07-10 | 2013-07-10 | Tri-salt form of metformin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015000368A2 true BR112015000368A2 (pt) | 2017-06-27 |
Family
ID=49916541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015000368A BR112015000368A2 (pt) | 2012-07-10 | 2013-07-10 | forma de tri-sais de metformina |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2872483A4 (enExample) |
| JP (1) | JP2015523382A (enExample) |
| KR (1) | KR20150036235A (enExample) |
| CN (1) | CN104684889A (enExample) |
| AU (1) | AU2013290168A1 (enExample) |
| BR (1) | BR112015000368A2 (enExample) |
| CA (1) | CA2878819A1 (enExample) |
| IL (1) | IL236613A0 (enExample) |
| IN (1) | IN2015KN00076A (enExample) |
| MX (1) | MX2015000408A (enExample) |
| WO (1) | WO2014011814A1 (enExample) |
| ZA (1) | ZA201500274B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014124141A1 (en) * | 2013-02-07 | 2014-08-14 | Mylari Banavara L | Metformin derivatives for treating diabetes |
| US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| EA201692548A1 (ru) * | 2014-06-18 | 2017-10-31 | ТЕТИС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Минеральные аминокислотные комплексы активных веществ |
| US20170119841A1 (en) * | 2015-11-04 | 2017-05-04 | Thetis Pharmaceuticals Llc | Amino acid salts of unsaturated fatty acids |
| DK3454907T3 (da) | 2016-06-03 | 2020-10-19 | Thetis Pharmaceuticals Llc | Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation |
| US10471963B2 (en) | 2017-04-07 | 2019-11-12 | TuSimple | System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle |
| US10737695B2 (en) | 2017-07-01 | 2020-08-11 | Tusimple, Inc. | System and method for adaptive cruise control for low speed following |
| CN113105367B (zh) | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
| CN114349665B (zh) * | 2021-11-30 | 2023-06-09 | 潍坊博创国际生物医药研究院 | 二甲双胍焦谷氨酸晶体及其制备方法与应用 |
| CN115192625A (zh) * | 2022-06-30 | 2022-10-18 | 山东海赜生物科技有限公司 | 一种口服组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2216335T3 (es) * | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
| FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
| WO2002012177A1 (en) * | 2000-08-03 | 2002-02-14 | Igor Anatolievich Pomytkin | Composition of metformin with succinic acid or salts thereof and method for treating diabetes |
| CN100415224C (zh) * | 2003-03-18 | 2008-09-03 | 诺瓦提斯公司 | 包含脂肪酸和氨基酸的组合物 |
| EP1591114A1 (en) * | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
| CN101855204B (zh) * | 2007-09-21 | 2013-09-11 | 韩兀生物制药株式会社 | N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物 |
| EP2229158B1 (en) * | 2007-12-20 | 2016-08-10 | Fertin Pharma A/S | Compressed chewing gum tablet |
| US20110082119A1 (en) * | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| SG175390A1 (en) * | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| WO2012054523A2 (en) * | 2010-10-19 | 2012-04-26 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US8796338B2 (en) * | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US20120178813A1 (en) * | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| WO2014124141A1 (en) * | 2013-02-07 | 2014-08-14 | Mylari Banavara L | Metformin derivatives for treating diabetes |
-
2013
- 2013-07-10 CA CA2878819A patent/CA2878819A1/en not_active Abandoned
- 2013-07-10 JP JP2015521784A patent/JP2015523382A/ja active Pending
- 2013-07-10 EP EP13817534.4A patent/EP2872483A4/en not_active Withdrawn
- 2013-07-10 CN CN201380046842.4A patent/CN104684889A/zh active Pending
- 2013-07-10 BR BR112015000368A patent/BR112015000368A2/pt not_active IP Right Cessation
- 2013-07-10 MX MX2015000408A patent/MX2015000408A/es unknown
- 2013-07-10 KR KR20157002264A patent/KR20150036235A/ko not_active Withdrawn
- 2013-07-10 WO PCT/US2013/049984 patent/WO2014011814A1/en not_active Ceased
- 2013-07-10 AU AU2013290168A patent/AU2013290168A1/en not_active Abandoned
- 2013-07-10 IN IN76KON2015 patent/IN2015KN00076A/en unknown
-
2015
- 2015-01-11 IL IL236613A patent/IL236613A0/en unknown
- 2015-01-14 ZA ZA2015/00274A patent/ZA201500274B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014011814A1 (en) | 2014-01-16 |
| EP2872483A4 (en) | 2016-03-16 |
| IL236613A0 (en) | 2015-02-26 |
| ZA201500274B (en) | 2017-10-25 |
| EP2872483A1 (en) | 2015-05-20 |
| IN2015KN00076A (enExample) | 2015-07-31 |
| CN104684889A (zh) | 2015-06-03 |
| AU2013290168A1 (en) | 2015-02-05 |
| KR20150036235A (ko) | 2015-04-07 |
| JP2015523382A (ja) | 2015-08-13 |
| CA2878819A1 (en) | 2014-01-16 |
| MX2015000408A (es) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015000368A2 (pt) | forma de tri-sais de metformina | |
| EA201591050A1 (ru) | Имидазопиридиновые соединения | |
| BR112012017073A2 (pt) | Método de tratamento de condições neurológicas com glicosídeos cardíacos | |
| BR112014016788A8 (pt) | composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa | |
| BR112017018187A2 (pt) | composições compreendendo combinações de ácidos orgânicos | |
| EP2623586A3 (en) | Compositions and methods for surface treatment with lipases | |
| MX340441B (es) | Proceso para tratar fibras queratinicas alaciadas. | |
| TN2015000158A1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
| BR112014032316A2 (pt) | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta | |
| BR112014009790A2 (pt) | composto para modulação antisense da expressão de gccr, seu uso e composição | |
| AR102463A1 (es) | Inhibidor de cinasa aurora a | |
| UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
| ECSP099039A (es) | Esteres de dha y su utilización en el tratamiento y la prevención de enfermedades cardiovasculares | |
| PE20151595A1 (es) | Compuestos de pirazol-amida y sus usos farmaceuticos | |
| PE20141452A1 (es) | Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan | |
| WO2015066426A3 (en) | Angiopoietin-based interventions for treating cerebral malaria | |
| EA201391592A1 (ru) | Местная композиция для лечения гиперкератотической кожи | |
| MX2016003445A (es) | Acidos poliasparticos modificados, la produccion de los mismos y su uso como dispersantes e inhibidores de incrustaciones en detergentes de lavado, detergentes de lavavajillas y composiciones de productos de limpieza, y en el tratamiento de aguas. | |
| BR112014002061A2 (pt) | processo de preparo de aminoácidos ou ésteres compreendendo uma etapa de metátese | |
| BR112014027047A2 (pt) | nova formulação | |
| CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
| BR112018012010A2 (pt) | composto, composição, método de controle de pragas invertebradas e semente tratada | |
| CR20120561A (es) | Composiciones y métodos para el diagnóstico y tratamiento de tumores | |
| BR112018004446A2 (pt) | método para produzir ácido poliaspártico, composição, e, uso do ácido poliaspártico. | |
| BR112017018113B8 (pt) | Composições compreendendo combinações de ácidos orgânicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |